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A B S T R A C T
Human methylmalonyl-CoA epimerase (MCEE) catalyzes the interconversion of D-methylmalonyl-CoA and L-
methylmalonyl-CoA in propionate catabolism. Autosomal recessive pathogenic variations in MCEE reportedly
cause methylmalonic aciduria (MMAuria) in eleven patients. We investigated a cohort of 150 individuals suf-
fering from MMAuria of unknown origin, identifying ten new patients with pathogenic variations in MCEE. Nine
patients were homozygous for the known nonsense variation p.Arg47* (c.139C > T), and one for the novel
missense variation p.Ile53Arg (c.158T > G). To understand better the molecular basis of MCEE deficiency, we
mapped p.Ile53Arg, and two previously described pathogenic variations p.Lys60Gln and p.Arg143Cys, onto our
1.8 Å structure of wild-type (wt) human MCEE. This revealed potential dimeric assembly disruption by
p.Ile53Arg, but no clear defects from p.Lys60Gln or p.Arg143Cys. We solved the structure of MCEE-Arg143Cys to
1.9 Å and found significant disruption of two important loop structures, potentially impacting surface features as
well as the active-site pocket. Functional analysis of MCEE-Ile53Arg expressed in a bacterial recombinant system
as well as patient-derived fibroblasts revealed nearly undetectable soluble protein levels, defective globular
protein behavior, and using a newly developed assay, lack of enzymatic activity - consistent with misfolded
protein. By contrast, soluble protein levels, unfolding characteristics and activity of MCEE-Lys60Gln were
comparable to wt, leaving unclear how this variation may cause disease. MCEE-Arg143Cys was detectable at
comparable levels to wt MCEE, but had slightly altered unfolding kinetics and greatly reduced activity. These
studies reveal ten new patients with MCEE deficiency and rationalize misfolding and loss of activity as molecular
defects in MCEE-type MMAuria.
1. Introduction
Propionyl-CoA is the common degradation product from branched-
chain amino acids, odd-chain fatty acids, and the side chain of cho-
lesterol. The propionate catabolic pathway serves to funnel propionyl-
CoA into the tricarboxylic acid (TCA) cycle for use as cellular energy
sources through oxidative phosphorylation. Located at the centre of this
pathway, methylmalonyl CoA epimerase (MCEE) catalyzes the epi-
merization of D-methylmalonyl-CoA, generated from propionyl-CoA by
propionyl-CoA carboxylase (PCC), to form L-methylmalonyl-CoA, sub-
sequently converted into succinyl-CoA by methylmalonyl-CoA mutase
(MUT) for entry into the TCA cycle.
Isolated methylmalonic aciduria (MMAuria), an inborn error of or-
ganic acid metabolism, is typically caused by deficiency of MUT or by a
defect in the transport or processing of its organometallic cofactor,
adenosylcobalamin. However, pathogenic variations in the human
MCEE gene (OMIM #251120) have been identified in eleven cases of
atypical MMAuria [1–6]. For two patients, coincidental variations in
the SPR gene causing sepiapterin reductase deficiency sufficiently ex-
plained their clinical symptoms [2,4], while two others have been de-
scribed as asymptomatic [3], leaving the clinical importance of MCEE
deficiency in doubt. The majority of patients with MCEE deficiency
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(seven including those with sepiapterin reductase deficiency) are
homozygous for the stop-gain nonsense variation c.139C > T
(p.Arg47*) [1–6]; the missense changes p.Lys60Gln and p.Arg143Cys
[3] and a splice altering variation (c.379-644A > G) [5] have also
been identified, but the functional relevance of these remains unclear.
In the human genome, MCEE is one of six proteins belonging to the
vicinal oxygen chelate (VOC) superfamily, which include also glyox-
alase I (GLO1 gene, GLOD1 protein), 4-hydroxyphenylpyruvic acid di-
oxygenase (HPD, GLOD3), 4-hydroxyphenylpyruvic acid dioxygenase-
like (HPDL, GLOXD1), and glyoxalase domain-containing 4 (GLOD4)
and 5 (GLOD5). VOC members are metalloenzymes highly divergent in
sequence and biological functions, but universally share the use of the
βαβββ structural motif (also known as the glyoxylase fold) to build a
divalent metal-containing active site [7,8]. VOC enzymes catalyze a
range of chemical reactions including isomerization, epimerization,
oxidative CeC bond cleavage and nucleophilic substitution [9]. The
active-site divalent metal is used to bind the reaction substrate, inter-
mediates or transition states in a bidentate fashion [8]. To date, only
structures from bacterial MCEE orthologues (Propionibacterium sher-
manii and Thermoanaerobacter tengcongensis) have been reported
[10,11].
In this article, we conducted an in depth investigation of MCEE
deficiency at the gene and protein levels. From a cohort of 150 patients
with MMAuria of unknown etiology, we identified ten new patients
with pathogenic variations on the MCEE gene including a novel mis-
sense change. We determined the crystal structure of human MCEE of
the wild-type as well as p.Arg143Cys variant proteins. We further
characterized protein expression and enzyme activity for the three
known MCEE missense changes associated with disease. Our study
provides a molecular explanation for the biochemical defects associated
with pathogenic missense variations.
2. Materials and methods
2.1. Reagents
Unless otherwise noted, all compounds were obtained from Sigma-
Aldrich (Buchs SG, Switzerland) and were reagent grade or better.
2.2. Purification, crystallization and structure determination of hMCEE
Human (h) MCEE was cloned, expressed and purified as previously
described [12]. Briefly, wt and variant proteins were expressed in Es-
cherichia coli BL21(DE3)R3-Rosetta cells from 3 to 6 l of Terrific Broth
culture. Cell pellets were lysed by high pressure homogenizer and
centrifuged at 35,000×g. The clarified cell extract was incubated with
2.5 ml of Ni-NTA resin pre-equilibrated with lysis buffer (50mM HEPES
pH 7.5, 500mM NaCl, 10mM Imidazole, 5% Glycerol, 0.5 mM TCEP).
The column was washed with 100ml Binding Buffer (50mM HEPES
pH 7.5, 500mM NaCl, 5% glycerol, 10 mM Imidazole, 0.5 mM TCEP),
50ml Wash Buffer (50mM HEPES pH 7.5, 500mM NaCl, 5% glycerol,
40 mM Imidazole, 0.5mM TCEP) and eluted with 15ml of Elution
Buffer (50mM HEPES pH 7.5, 500mM NaCl, 5% glycerol, 250mM
Imidazole, 0.5mM TCEP). The eluant fractions were concentrated to
5ml and applied to a Superdex 200 16/60 column pre-equilibrated in
GF Buffer (10mM HEPES pH 7.5, 500mM NaCl, 0.5mM TCEP, 5%
glycerol). Eluted protein fractions were incubated with 1:20mol:mol
TEV protease overnight at 4 °C. The next day sample was passed
through 0.5ml Ni-NTA pre-equilibrated with GF Buffer and washed
1ml of GF Buffer. Flow-through and wash were pooled and con-
centrated to 10–15mg/ml.
Crystals of hMCEEWT were grown by vapour diffusion in sitting drop
at 20 °C. A sitting drop consisting of 75 nl protein and 75 nl well solu-
tion was equilibrated against well solution containing 30% (v/v) low
molecular weight PEG smear [13] and 0.1M Tris pH 8.5. Crystals were
mounted in the presence of 25% (v/v) ethylene glycol and flash-cooled
in liquid nitrogen. Crystals of hMCEER143C were grown by vapour dif-
fusion in sitting drop at 20 °C. A sitting drop consisting of 50 nl protein
and 100 nl well solution was equilibrated against well solution con-
taining 20% PEG4000, 10% 2-propanol and 0.1M HEPES pH 7.5.
Crystals were mounted in the presence of 25% (v/v) ethylene glycol and
flash-cooled in liquid nitrogen. Crystallization and diffraction data are
given in Table 2. The structure of hMCEEWT was solved by molecular
replacement using PHASER [14], with P. shermanii MCEE structure
(PDB 1JC5) as search model. The structure of hMCEER143C was solved
by molecular replacement with hMCEEWT as search model. Iterative
cycles of refinement and manual model building were performed using
COOT [15], REFMAC5 [16] and phenix.refine [17].
2.3. Size exclusion chromatography
Size exclusion chromatography was performed as described in [18].
2.4. Nano-differential scanning fluorimetry
Melting curves for the wt protein and mutants were obtained via
detection of changes in light scattering using the Prometheus NT.48.
Protein concentration was kept at 100 μM in 50mM HEPES pH 7.5,
500mM NaCl, 0.5mM TCEP, 5% glycerol and a melt gradient of 1° per
minute 20 °C to 95 °C was used.
2.5. Patient characterization (genotyping, propionate incorporation)
Skin fibroblasts were taken from patients with biochemical and
clinical evidence of methylmalonic aciduria, referred to our institution
for diagnostic purposes. The study has been approved by the ethics
commission of the Canton of Zurich, Switzerland (application no. 2014-
0211). Genomic DNA and RNA extraction, as well as sequencing and
propionate incorporation were performed as previously described [18].
The nomenclature of the variation is based on the cDNA sequence
NM_032601.3. Nucleotide numbering uses +1 as the A of the ATG
translation initiation codon in the reference sequence, with the initia-
tion codon as codon 1.
2.6. Transfection, immunoblotting and enzymatic assay
A DNA fragment encompassing the entire coding sequence of wild-
type MCEE was cloned into pcDNA3-CT10HF-LIC using LIC cloning.
The sequence was as given by NM_032601.3, except for c.311 T > G
(p.Leu104Arg), whereby c.311G is the more common allele, [19]. Site-
directed mutagenesis was carried out on this construct using the
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) as
described in the manufacturer's instructions, using forward and reverse
primers (Microsynth, Balgach, Switzerland) and confirmed by Sanger
sequencing. Control (BJ, CRL-2522, ATCC) or patient (carrying homo-
zygous MCEE c.139C > T, p.Arg47*) fibroblasts were transiently
transfected with 10 μg wild-type or mutant MCEE constructs, with or
without 10 μg MUT in pTracer [20] for the enzymatic assay, using
electroporation [21]. Cells were grown in Dulbecco's Modified Eagle
Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco)
and antibiotics (GE Healthcare), as previously described [22] and
harvested by trypsinization 48 h after electroporation, washed twice
with HBSS (Gibco) and either frozen at −20 °C or processed directly.
Western Blot analysis was performed on fresh or frozen cell pellets
essentially as described in [20], with the exception that monoclonal
anti-flagM2 (1:4,000; Sigma–Aldrich) and anti-β-Actin (at 1:5,000;
Sigma–Aldrich) were used.
For the enzymatic assay, fresh or frozen cell pellet was lysed in
buffer including 12mM Tris-HCl, pH 8.0 and 1mM DTT with sonication
twice at amplitude 1.5 for 15 s using the microprobe of an XL-2000
sonicator (Microson, Qsonica Newtown, CT). Following lysis, protein
concentration was determined by the Lowry method. The incubation
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mixture contained 300–500 μg cell protein, reaction buffer (100mM
Tris-HCl, pH 8.0; 6mM MgCl2; 3.15mM ATP; 100mM KCl; 3mM DTT),
1mM propionyl-CoA mix (1mM propionyl-CoA and 7 μM [14C]-pro-
pionyl-CoA at 55mCi/mmol, Anawa, Switzerland) and 50 uM adeno-
sylcobalamin and reaction time was 60min at 37 °C. The reaction was
stopped by adding 0.5M KOH, samples were then re-incubated for
15min at 37 °C to hydrolyze CoA derivatives, neutralized by adding
0.5 N perchloric acid (Merck), and spiked with 0.05% succinic acid,
0.018% methylmalonic acid and 0.018% propionic acid in order to
visualize peaks during HPLC separation. Samples were centrifuged to
remove precipitate, and supernatant was injected into an Aminex HPX-
87H Ion Exclusion column (300× 7.8mm2; H-form, 9 μm, Bio-Rad),
and organic acids separated by elution with 0.5mM H2SO4 at 30 °C
using a flow rate of 0.4 ml/min. Retention times were 13–15min for
methylmalonic acid, 17–19min for succinic acid, and 26–28min for
propionic acid (Supplemental Fig. S5 and 6), visualized at 210 nm using
a UV detector. Fractions covering the methylmalonic acid and succinic
acid peaks were collected and [14C]-methylmalonic acid and [14C]-
succinic acid quantified in a Tri-Carb C1 900TR scintillation spectro-
meter (PerkinElmer,Waltham, MA, USA) with OptiphaseHiSafe 2
counting cocktail (PerkinElmer).
3. Results & discussion
3.1. Identification of ten new MCEE patients with methylmalonic aciduria
Thus far, 11 cases of MMAuria have been identified due to patho-
genic variations in the MCEE gene [1–6]. We screened fibroblast cell
lines taken from 150 patients with mild but clear MMAuria who could
not be assigned to a cobalamin class of defect. From this cohort, we
identified ten patients from nine families with pathogenic variations in
MCEE (Table 1). Nine patients were homozygous for the c.139C > T
(p.Arg47*) nonsense variation, which has been previously described.
This remains by far the most common pathogenic variation identified in
MCEE deficiency, with 16 out of 21 patients homozygous for this allele.
One patient in our cohort was homozygous for c.158 T > G
(p.Ile53Arg), a novel missense variation that is not found in the ExAC
database (> 120,000 alleles) [19]. We did not observe either
c.178A < C (p.Lys60Gln), previously found in one patient in the
homozygous state, or c.427C > T (p.Arg143Cys), previously found in
two patients in the heterozygous state without an apparent second
disease causing variation [3].
In our cohort, disease onset ranged from 1month old to 2.5 years of
age, while from two patients we had no information. Clinical symptoms
were variable but usually mild, and no patient was responsive to vi-
tamin B12 treatment. At least three patients presented following an
intercurrent illness, while three presented with metabolic acidosis and/
or hypoglycemia. In addition, elevated levels of other metabolites ty-
pical for a block in the propionate degradation pathway, such as 2-
methylcitrate, propionylcarnitine and 3-hydroxypropionate, were
documented in most patients. Investigation in patient fibroblasts re-
vealed mildly decreased propionate incorporation (Table 1), which did
not increase upon addition of hydroxocobalamin.
3.2. Structural features of human MCEE
We performed structural biology studies to establish the molecular
basis of disease-causing variations on the human MCEE protein
(hMCEE). As a first step, we determined the crystal structure of wild-
type (wt) protein (hMCEEWT) to 1.8 Å resolution (Table 2), as part of a
wider effort that also generated crystal structures of three other human
VOCs, namely hHPD (PDB: 3ISQ), hGLOD4 (PDB 3ZI1) and hGLOD5
(PDB 3ZW5). Most VOC members are structurally made up of four
glyoxylase (GLOD) motifs of βαβββ topology. As exemplified in Sup-
plemental Fig. S1, the human VOCs display versatility in the way that
four GLOD motifs are assembled, at the gene or protein level, to give Ta
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rise to a minimal functional unit harbouring two metal-binding active
sites.
In the case of hMCEE, two βαβββ motifs pack side-by-side to form
an 8-stranded sheet that completes the active site for one protomer
(Fig. 1A). Crystallographic (Supplemental Fig. S1) and solution data
(Supplemental Fig. S2) show that hMCEE is dimeric, in agreement with
bacterial orthologs [10,11]. The VOC members are so called because a
divalent metal per active site can bind the substrate, intermediates or
transition states in a bidentate fashion [8]. The divalent metal ion in
hMCEE, observed as cobalt in our structure, is coordinated by three
residues strictly conserved among VOCs: His50 (strand β1), His122
(strand β5), and Glu172 (strand β8) (Fig. 1B).
3.3. Structural mapping of missense variations
Both the reported p.Arg143Cys and newly identified p.Ile53Arg
missense changes are predicted by SIFT (Damaging, score: 0.00 & 0.01)
and PolyPhen2 (Probably damaging, score: 0.989 & 1.00) to be dele-
terious. By contrast, the other previously reported p.Lys60Gln variation
was predicted to be not deleterious (SIFT: 0.12 tolerated, PolyPhen2:
0.04 benign). The most common pathogenic variation of MCEE,
c.139C > T, causes truncation of the protein at p.Arg47*, within the
first β-sheet (Supplemental Fig. S3). Loss of almost the entire protein is
therefore the likely cause of enzymatic dysfunction due to this varia-
tion, assuming there is residual mRNA following nonsense-mediated
decay.
By contrast, the molecular dysfunction due to the missense varia-
tions is less clear (Fig. 1C). In our hMCEE structure, Ile53 is located at
the dimeric interface, making hydrophobic contacts with Gly168 and
Val169 from the loop region connecting strands β7 and β8 (loopβ7-β8) of
the other subunit in the dimer, (Fig. 1D). The amino acid (aa) position
of Ile53 is highly conserved among MCEE orthologues (85% occupied
by Ile, n= 150). An Ile-to-Arg at this position likely interferes with
proper dimeric assembly, and is predicted by FoldX [23] to have se-
verely reduced stability (ΔΔG 9.53 kcal/mol). By contrast, Lys60 and
Arg143 occupy amino acid positions that are more variable. Position 60
is only occupied by lysine in 15% of MCEE homologs while position 143
is 60% occupied by arginine. Both residues are surface exposed and not
directly involved in the dimeric interface and active-sites of both sub-
units (Fig. 1D), consistent with a FoldX prediction of no effect for
p.Lys60Gln (ΔΔG 0.3 kcal/mol), and moderately reduced stability for
p.Arg143Cys (ΔΔG 2.26 kcal/mol).
Table 2
Data collection and refinement statistics for the crystal structures. Data from
highest resolution shell shown in parenthesis.
Dataset hMCEEWT hMCEER143C
Beamline Diamond beamline
I02
Diamond beamline I04
Wavelength (Å) 0.9763 0.9795
Unit cell parameters (a,b,c) 53.12 Å, 66.69 Å,
76.98 Å
53.16 Å, 66.99 Å,
77.13 Å
(α, β, γ) 90.0°, 90.1°, 90.0° 90.00°, 90.02°, 90.00°
Space group P 1 21 1 P 1 21 1
Resolution range (Å) 36.58–1.80 77.13–1.92a
Observed/Unique reflections 49,519 19,630
Rsym (%) 0.076 (0.56) 0.13 (0.92)
I/sig(I) 1.98 7.2 (1.2)
Completeness (%) 99.2 (99.7) 88.9 (55.8)
Multiplicity 3.6 (3.6) 3.3 (2.7)
Rcryst (%) 0.19 0.23
Rfree (%) 0.238 0.28
Wilson B factor (Å2) 23.7 25
Average total B factor (Å2) 27.59 35.6
R.m.s.d. bond length (Å2) 0.67 0.003
R.m.s.d. bond angle (°) 0.69 0.588
Missing residues 1–44 1–44
Clashscore 6 4.29
Ramachadran favoured (%) 97 99
Ramachandran disallowed
(%)
1 0
Rotamer outliers (%) 0 0
a Anisotropic data truncated in staraniso using local I/sigI cut off at 1.2 re-
sults in the inclusion of data to 1.9 Å with outer-shell ellipsoidal completeness
at 58.8% and spherical completeness at 10%.
Fig. 1. Structure of hMCEE (PDB ID:3RMU). A. Monomeric structure coloured by secondary structure, whereby β-strands are green, α-helices that are part of the
GLOD motif are red, and regions that connect GLOD motifs are yellow. B. Active-site architecture showing the divalent metal and metal coordinating residues. Pink
sphere: cobalt. C. On the hMCEE monomer, residues that are mutated in disease are labeled in orange, active-site residues are labeled in black. D. hMCEE phy-
siological dimer with the second subunit represented as grey space fill. Missense changes are labeled in orange and designated as belonging to chain (monomer) A or
B.
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3.4. Structure of human MCEE p.Arg143Cys variant
We determined the crystal structure of the p.Arg143Cys variant
protein (hMCEER143C) to 1.9 Å resolution (Table 2), to directly inspect
the atomic environment of the substitution (Fig. 4). While hMCEER143C
superimposes well overall with hMCEEWT (Cα-RMSD 0.278 Å), sig-
nificant main-chain displacement was clearly observed in the loop re-
gion connecting helix α3 and β6 (loopα3-β6) that harbours the site of
change at aa 143, as well as the nearby loopβ7-β8 (Fig. 2, inset). These
loop regions connect several β-strands that make up the protomer ac-
tive site. In the hMCEER143C structure, the substituted Cys143 residue
generated more mobility and disorder within the loopα3-β6. As a result,
the main-chain atoms of aa 142–146 are displaced by ~2.5–4.7 Å
compared to hMCEEWT. The increased mobility in loopα3-β6 impacts on
the nearby loopβ7-β8 that packs against it, resulting in 2.0–4.8 Å main-
chain displacement at the first half of loopβ7–β8 (aa 164–167). The
second half of loopβ7–β8, involved in the aforementioned dimeric in-
terface, was not affected by any displacement. Together, these local
structural changes have the potential to impact on the surface features
of the homodimer, as well as the active site pocket.
3.5. Characterization of missense variations in recombinant and patient
cells
To validate our structural interpretation, we performed expression
studies in E. coli and human cells. When expressed in E. coli (Fig. 3A),
hMCEE wt, p.Lys60Gln and p.Arg143Cys proteins were highly soluble,
while the p.Ile53Arg variant showed a massive decrease in protein so-
lubility, consistent with a poorly folded protein. All wt and variant
hMCEE molecules eluted at similar volumes by size exclusion chro-
matography (Supplemental Fig. S4). Thermal unfolding (Fig. 3B) of
purified hMCEE p.Ile53Arg by nano-differential scanning fluorimetry
revealed a melting curve of multiple transitions, indicative of hetero-
genous protein states. By contrast, purified wt and p.Lys60Gln proteins
showed globular protein behaviour reflected by a cooperative sigmoidal
melting pattern, indicating a single unfolding/folding transition.
p.Arg143Cys also behaved similarly to wt and p.Lys60Gln, however late
stage unfolding/folding intermediates deviate from sigmoidal melting.
Together our data indicate reduced thermostability for the p.Ile53Arg
variant protein and a potential slight alteration in that of p.Arg143Cys.
These results were validated by over-expression of hMCEE in patient
fibroblasts homozygous for the MCEE null variant (c.139C > T;
Fig. 2. Structure of hMCEE p.Arg143Cys variant (PDB ID:6QH4). Structural superposition of hMCEE homodimer from hMCEEWT (yellow) and hMCEER143 (cyan)
proteins. Inset. Magnified view of the local atomic environment surrounding the Arg143/Cys143 site, where amino acid side-chains are shown as thin lines.
Fig. 3. Characterization of recombinant hMCEE wt and variant proteins. A. SDS-PAGE analysis of hMCEE protein expression (from cell lysate: Total Lysis; and
centrifuged supernatant fractions: Soluble) and solubility (from eluant fractions of affinity purification); B. nanoDSF melting curve plot of normalized light scattering
intensity against temperature.
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p.Arg47*). For this experiment, flag-tagged wt and mutant hMCEE
proteins were over-expressed with visualization of the flag-tag by
Western blot analysis (Fig. 4A). Expression of each construct performed
at least 3 times revealed wt protein to be well expressed, while hMCEE
containing p.Lys60Gln and p.Arg143Cys were detectable at only
slightly lower levels (63 ± 17% and 74 ± 26% of wt, respectively)
(Fig. 4B). However, hMCEE containing p.Ile53Arg had very low levels
of detectable protein (6 ± 1% of wt), similar to empty vector (4 ± 2%
of wt) (Fig. 4B). Thus, consistent with recombinant studies, it appears
that p.Ile53Arg causes an inability to fold correctly.
3.6. Biochemical characterization of missense variations
We developed a radioactive HPLC-based assay to assess MCEE ac-
tivity of wt and variants. This assay follows the production and se-
paration of [14C]-methylmalonic acid and [14C]-succinic acid from
[14C]-propionic acid following addition of [14C]-propionyl-CoA to fi-
broblast cell lysates, as depicted in Fig. 5A. Using UV detection, we
were able to detect separated propionic acid, methylmalonic acid and
succinic acid following HPLC analysis (Supplemental Fig. S5). In cell
lysates from control fibroblasts, we identified high levels of [14C]-me-
thylmalonic acid but only very little [14C]-succinic acid (Fig. 5B;
Fig. 4. Over-expression of hMCEE-flag in human fibroblasts. A. Representative Western blots depicting detection of wild-type (wt) or mutant hMCEE-flag following
over-expression in patient fibroblasts deficient for MCEE enzyme. Vector without insert was used as a control (e.v.). Loading was controlled by detection of
endogenous β-actin. Numbers on the left correspond to molecular weights (kDa). Approximate expected molecular weights, hMCEE-flag: 18 kDa; β-actin: 42 kDa. B.
Bar-graph depicting mean and standard deviation of Western blot results performed in 3 independent experiments.
Fig. 5. Biochemical analysis of hMCEE disease associated variations. A. Schematic depiction of the cellular pathway leading from propionyl-CoA to succinyl-CoA and
the enzymes involved in this process. B and C. Bar-graph showing the amount of methylmalonic acid (MMA) and succinate following over-expression of empty vector
(e.v.), methylmalonyl-CoA mutase (MUT) alone, MCEE alone, or both MCEE and MUT in control fibroblasts (B) and patient fibroblasts deficient in MCEE (C). D. Bar
graph depicting production of MMA and succinate following over-expression of wild-type (wt) and mutant MCEE in the presence of over-expressed MUT in MCEE
patient fibroblasts. Results shown represent the mean and standard deviation of 3 independent experiments.
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Supplemental Fig. S6A). To determine if MUT or MCEE was rate-lim-
iting for succinate production, we expressed each individually, or to-
gether (Fig. 5B; Supplemental Fig. S6B–C). While over-expressed MUT-
alone only marginally increased detectable [14C]-succinic acid, MCEE
expression alone, and especially co-expression with MUT, provided a
marked increase in [14C]-succinic acid (Fig. 5B; Supplemental Fig. 6D).
Therefore, MCEE appears to be the rate-limiting step in this pathway.
This same basic pattern could be seen in MCEE null fibroblasts
(Fig. 5C).
We further examined the effect of the mutant MCEE proteins in the
presence of over-expressed MUT in MCEE null fibroblast lysates
(Fig. 5D). Over-expression of MCEE harbouring p.Ile53Arg resulted in
very little detectable [14C]-succinate. This is consistent with an inability
to convert D-methylmalonyl-CoA to L-methylmalonyl-CoA due to a lack
of correctly folded protein, as was demonstrated by Western blot ana-
lysis. By contrast, over-expressed MCEE harbouring p.Lys60Gln pro-
duced similar levels of detectable succinate as wt protein. Finally, de-
spite being well expressed, MCEE harbouring p.Arg143Cys had
markedly reduced [14C]-succinic acid production, agreeing with the
significantly altered local environment in the hMCEER143C structure.
This conformational change could impair enzymatic activity of
p.Arg143Cys either by direct structural interference with the active site,
or indirectly e.g. via loss of essential interactions with other proteins in
the succinyl-CoA production pathway.
4. Conclusions
The identification of an additional ten patients with MCEE defi-
ciency adds more information toward the debate of whether deficiency
of this protein does indeed cause disease and not just elevated me-
thylmalonic acid levels. It also confirms that complete MCEE defi-
ciency, despite incomplete penetrance, may be associated with an acute
clinical phenotype with metabolic crisis resembling classical organic
acidurias. However, in comparison to the most frequent organic acid-
urias (e.g. complete methylmalonyl-CoA deficiency, propionic acid-
emia), MCEE deficiency is clearly clinically less severe [24]. Our
combined structural, biophysical and enzymatic assessment of MCEE
defects confirm the importance of this protein within the propionate
degradation pathway. While protein-destabilizing variations (e.g.
p.Ile53Arg) explains enzymatic defects more readily, those away from
the active-site (e.g. p.Arg143Cys) could still cause a loss of activity,
although the underlying mechanism needs further clarification. With
regard to p.Lys60Gln, however, we could identify no defect conferred to
the protein. While we cannot rule out potential effects on mRNA spli-
cing or protein-protein interactions, the molecular mechanism of dis-
ease caused by this variation remains unexplained.
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